Pshea7138's Profile
Displaying 351-400 of 664 result(s).
Go to page:
Recent Articles
- Exploring the Evolution of Urban-Rural Transport in China
- DDB Capital Enhances Investment Focus in North Alabama Housing
- Anticipation Grows for the 2nd China-Central Asia Summit
- Revitalizing Heritage: A Journey Through Dunhuang's Culture
- Abbisko Therapeutics Advances Irpagratinib Study for HCC Treatment
- China to Host 6th Multinationals Summit, Encouraging Investment
- SDP Japan Secures $31 Million to Transform Surgical Care
- Tokyo Gas Triumphs in Cloud Native Case Study Competition
- Significant Subgroup Analysis of Cadonilimab in Cervical Cancer
- Stavian Chemical Achieves Major Milestone in Global Rankings
- ArkBio's Azstarys Approved for ADHD Treatment Review in China
- Strategic Thinking in China's Development Plans and Governance
- Industrial Lubricants: Insights and Future Market Trends Ahead
- Innovent's Mazdutide Advances with First Patient Dosed in Trial
- Innovative Treatment Strategies Highlighted at EHA 2025 Conference
- Celltrion Gains FDA Nod for New STEQEYMA® Pediatric Formulation
- Innovative Drug Screening Services Introduced by Samsung Biologics
- Transforming Transit: $4 Billion to Electrify Buses in Canada
- Abaxx Technologies Launches Innovative Gold Futures Trading
- 2025 Meijer LPGA Classic Makes Impact with $1.5 Million
- Bombardier's Global 7500 Establishes New Speed Benchmark
- IDEX Biometrics ASA Announces Significant Share Issuance to Personnel
- Investors Urged to Join Class Action Against West Pharmaceutical Services
- Honoring Leonard A. Lauder: A Legacy in Alzheimer's Research
- Elevate Your Earnings with PFMCrypto's Exciting XRP Giveaway
- AIXA Miner Celebrates Groundbreaking Milestone in Green Mining
- Oma Savings Bank Plc Revises Profit Outlook: Important Update
- Transformative Leadership Change at Renault Group Announced
- Deadline for Fortrea Holdings Inc. Investors in Lawsuit Ahead
- Dupixent® Triumphs in Phase 4 Trial Against Xolair® for CRSwNP
- Dupixent vs. Xolair: Breakthrough Findings in Asthma Treatment
- Faruqi & Faruqi Investigates Ibotta's Legal Claims for Investors
- Red Cat Holdings Faces Legal Challenges Amid Investor Concerns
- Investor Alert: Key Updates on Iovance Biotherapeutics Lawsuit
- Investors Alert: Faruqi & Faruqi Advocate for Open Lending Claims
- Compass Diversified Investors Encouraged to Act Before Deadline
- Freedom Holding Corp. Sees Strong Financial Growth in 2025
- Intellia's Lonvo-z Shows Promising Results for HAE Treatment
- Important Update for Rocket Pharmaceuticals Investors
- DoubleVerify Investors Urged to Consider Legal Options Now
- Investing in Zenas BioPharma: What Investors Should Know
- Deadline for NET Power Investors: What's Next After Losses?
- Investors Urged to Act: Krispy Kreme Legal Investigation Update
- Investigating Investor Claims on Avis Budget Group's Financials
- Urgent Investor Insights: Fortrea Holdings Under Scrutiny
- Investor Alert: Examining West Pharmaceutical Services Fraud Claims
- Vital Insights on Napco Security Technologies for Investors
- Urgent Alert: Investors of PepGen Should Act Now
- Critical Update for Civitas Resources Investors Amid Legal Scrutiny
- UroGen Investors Urged to Act Before Class Action Deadline
